Lead Sponsor

EMD Serono Research & Development Institute, Inc.

Collaborators

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Male or female participants greater than or equal to (\>=)18 years
•Signed informed consent
•Have diagnosis of RMS including RRMS and aSPMS and satisfy the approved indication for cladribine tablets as per United States Prescribing Information (USPI)
•Have time since diagnosis of RMS of at least 12 months
•Had received their last previous injectable disease-modifying drug (DMD) for at least 3 months
•Have decided to initiate treatment with cladribine tablets during routine clinical care
•Meet criteria as per the approved USPI
•Have access to a valid e-mail address
•In the opinion of the Investigator, experienced suboptimal response (lack of effectiveness, intolerability, poor adherence) to injectable DMD treatment

•Have been previously treated with cladribine in any dosing form
•Transitioning from previous injectable DMD solely for administrative reasons such as relocation
•Have comorbid conditions that preclude participation
•Have any clinical condition or medical history noted as contraindication on USPI
•Are currently participating in an interventional clinical trial
•Pregnant or breastfeeding women, women who plan to become pregnant or men whose partner plans to become pregnant during the cladribine treatment period